Late-term topical tacrolimus for subepithelial infiltrates resistant to topical steroids and ciclosporin secondary to adenoviral keratoconjunctivitis.

CONCLUSION: Topical 0.03% tacrolimus might show efficacy against the SEIs persisting at least 2 years despite corticosteroid and/or CSA treatment without any prominent side effect. While at least a period of 3 months was necessary for a significant improvement in the BCVA, SEIs and Schirmer results, a period of 6 months was necessary for a decrease in Oxford score. PMID: 32563992 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/32563992?dopt=Abstract

Source: The British Journal of Ophthalmology - June 19, 2020 Category: Opthalmology Authors: Arici C, Mergen B Tags: Br J Ophthalmol Source Type: research